Carrie Cuttler1, Alexander Spradlin2, Ryan J McLaughlin3. 1. Washington State University, Department of Psychology, P.O. Box 644820, Pullman, WA 99164-4820, USA; Translational Addiction Research Center, Washington State University, USA. Electronic address: carrie.cuttler@wsu.edu. 2. Washington State University, Department of Psychology, P.O. Box 644820, Pullman, WA 99164-4820, USA. 3. Washington State University, Department of Psychology, P.O. Box 644820, Pullman, WA 99164-4820, USA; Translational Addiction Research Center, Washington State University, USA; Washington State University, Department of Integrative Physiology and Neuroscience, Pullman, WA 99164-7620, USA.
Abstract
BACKGROUND: Cannabis is commonly used to alleviate symptoms of negative affect. However, a paucity of research has examined the acute effects of cannabis on negative affect in everyday life. The current study provides a naturalistic account of perceived changes in symptoms of depression, anxiety, and stress as a function of dose and concentration of Δ9tetrahydrocannabinol (THC) and cannabidiol (CBD). METHOD: Data from the app StrainprintTM (which provides medical cannabis users a means of tracking changes in symptoms as a function of different doses and chemotypes of cannabis) were analyzed using multilevel modeling. In total, 11,953 tracked sessions were analyzed (3,151 for depression, 5,085 for anxiety, and 3,717 for stress). RESULTS: Medical cannabis users perceived a 50% reduction in depression and a 58% reduction in anxiety and stress following cannabis use. Two puffs were sufficient to reduce ratings of depression and anxiety, while 10+ puffs produced the greatest perceived reductions in stress. High CBD (>9.5%)/low THC (<5.5%) cannabis was associated with the largest changes in depression ratings, while high CBD (>11%)/high THC (>26.5%) cannabis produced the largest perceived changes in stress. No changes in the perceived efficacy of cannabis were detected across time. However, baseline symptoms of depression (but not anxiety or stress) appeared to be exacerbated across time/tracked sessions. LIMITATIONS: The primary limitations are the self-selected nature of the sample and the inability to control for expectancy effects. CONCLUSIONS: Cannabis reduces perceived symptoms of negative affect in the short-term, but continued use may exacerbate baseline symptoms of depression over time.
BACKGROUND: Cannabis is commonly used to alleviate symptoms of negative affect. However, a paucity of research has examined the acute effects of cannabis on negative affect in everyday life. The current study provides a naturalistic account of perceived changes in symptoms of depression, anxiety, and stress as a function of dose and concentration of Δ9tetrahydrocannabinol (THC) and cannabidiol (CBD). METHOD: Data from the app StrainprintTM (which provides medical cannabis users a means of tracking changes in symptoms as a function of different doses and chemotypes of cannabis) were analyzed using multilevel modeling. In total, 11,953 tracked sessions were analyzed (3,151 for depression, 5,085 for anxiety, and 3,717 for stress). RESULTS: Medical cannabis users perceived a 50% reduction in depression and a 58% reduction in anxiety and stress following cannabis use. Two puffs were sufficient to reduce ratings of depression and anxiety, while 10+ puffs produced the greatest perceived reductions in stress. High CBD (>9.5%)/low THC (<5.5%) cannabis was associated with the largest changes in depression ratings, while high CBD (>11%)/high THC (>26.5%) cannabis produced the largest perceived changes in stress. No changes in the perceived efficacy of cannabis were detected across time. However, baseline symptoms of depression (but not anxiety or stress) appeared to be exacerbated across time/tracked sessions. LIMITATIONS: The primary limitations are the self-selected nature of the sample and the inability to control for expectancy effects. CONCLUSIONS: Cannabis reduces perceived symptoms of negative affect in the short-term, but continued use may exacerbate baseline symptoms of depression over time.
Authors: Kevin F Boehnke; J Ryan Scott; Evangelos Litinas; Suzanne Sisley; David A Williams; Daniel J Clauw Journal: J Pain Date: 2019-09-24 Impact factor: 5.820
Authors: Patrick M Azcarate; Alysandra J Zhang; Salomeh Keyhani; Stacey Steigerwald; Julie H Ishida; Beth E Cohen Journal: J Gen Intern Med Date: 2020-04-06 Impact factor: 5.128
Authors: Rachel L Tomko; Nathaniel L Baker; Caitlyn O Hood; Amanda K Gilmore; Erin A McClure; Lindsay M Squeglia; Aimee L McRae-Clark; Susan C Sonne; Kevin M Gray Journal: Psychopharmacology (Berl) Date: 2019-11-11 Impact factor: 4.530
Authors: Dennis J Sholler; Justin C Strickland; Tory R Spindle; Elise M Weerts; Ryan Vandrey Journal: Addict Biol Date: 2020-09-28 Impact factor: 4.280
Authors: Liangsuo Ma; John M Hettema; Janna Cousijn; James M Bjork; Joel L Steinberg; Lori Keyser-Marcus; Kyle Woisard; QiQi Lu; Roxann Roberson-Nay; Antonio Abbate; F Gerard Moeller Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2020-10-07